- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02159222
Sepsis Trial of Early Physical Therapy Outside the ICU (STEP TO IT)
October 14, 2019 updated by: Jeffrey Rohde, University of Michigan
Sepsis Trial of Early Physical Therapy Outside the ICU: A Pilot Feasibility Study
The purpose of this study is to determine whether an additional physical therapy program can improve the mobility and functional outcomes of patients diagnosed with severe sepsis (an illness in which the body has a severe response to bacteria or other germs and develops worsened function of a major organ such as the kidneys, heart, or lungs).
Study Overview
Detailed Description
Patients who are admitted to the hospitalist service at the University of Michigan Hospital will be screened for the presence of severe sepsis.
Those who are deemed eligible and provide consent will be enrolled.
Study patients will receive additional physical therapy according to a protocol developed for this study in addition to the usual care recommended by their regular treating physician.
Additional treatments will be individualized based on enrolled patients' baseline physical function and progress and may include standing, stretching, transferring, and walking - either with assistance or independently.
Treating therapists have been trained in the use of the protocol and individualization to maintain the highest standard of patient safety.
Patients will be contacted 30 days after discharge to answer questions about their health and ability to perform routine tasks at home.
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48105
- University of Michigan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Any English-speaking patient over the age of 18 who is currently admitted to a general care floor under the care of the Medicine Faculty Hospitalist Service at the University of Michigan Health System and has severe sepsis is eligible to take part in this study.
Exclusion Criteria:
- Subjects must be deemed by the study team to give informed consent by being able to state the basic purpose of the study. Consent by a legally authorized representative (LAR) will not be sought.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Additional physical therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline ambulation
Time Frame: At day 0 (baseline enrollment) and for the duration of the participants' hospitalization, a predicted average length of stay of 5 days.
|
Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days.
This outcome will be assessed at baseline and at each study protocol physical therapy session during the index hospitalization.
|
At day 0 (baseline enrollment) and for the duration of the participants' hospitalization, a predicted average length of stay of 5 days.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Activities of Daily Living (ADLs) and Instrumental Activities of Daily Living (iADLs)
Time Frame: At day 0 (baseline enrollment) and day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days)
|
Baseline ADLs will be assessed using chart review.
30 day follow-up ADL and iADL function will be assessed using a telephone survey
|
At day 0 (baseline enrollment) and day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days)
|
Discharge location
Time Frame: At day 5 (assessed at discharge; predicted average length of stay is 5 days)
|
The location of discharge (home, subacute rehabilitation facility, skilled nursing facility) will be assessed at discharge for all patients enrolled in the study.
|
At day 5 (assessed at discharge; predicted average length of stay is 5 days)
|
ICU Transfer Rate
Time Frame: Participants will be followed for the duration of their hospitalization, an average length of stay of 5 days.
|
The rate at which patients require transfer to the ICU will be assessed.
|
Participants will be followed for the duration of their hospitalization, an average length of stay of 5 days.
|
Length of stay
Time Frame: Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days.
|
The length of stay will be recorded for patients enrolled in the trial.
|
Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days.
|
Employment status
Time Frame: At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
|
For patients employed for pay prior to the index admission, employment status will be assessed by telephone survey 30 days post-discharge.
|
At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
|
Post-hospitalization physical function
Time Frame: At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
|
Patients' physical function will be assessed 30 days after discharge using the SF-10 instrument.
|
At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Readmission
Time Frame: At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
|
At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
|
|
In-Hospital Mortality
Time Frame: Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days
|
Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days
|
|
Falls
Time Frame: Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days.
|
Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days.
|
|
Arrhythmia
Time Frame: During each study protocol physical therapy session while hospitalized
|
Clinically significant arrhythmias occurring during therapy sessions will be documented and recorded as a safety outcome.
|
During each study protocol physical therapy session while hospitalized
|
Pressure ulcers
Time Frame: Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days.
|
The presence and severity of pressure ulcers will be recorded.
|
Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days.
|
Cognitive function
Time Frame: At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
|
Enrolled patients' cognitive function will be assessed using the TICS-m instrument
|
At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
|
Depression
Time Frame: At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
|
Patients will be screened for depression using the PHQ-2 instrument as part of the follow-up telephone survey.
|
At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
|
30-Day Post-Hospitalization Mortality
Time Frame: At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
|
At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Andrew Odden, MD, University of Michigan
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2014
Primary Completion (Actual)
September 1, 2019
Study Completion (Actual)
September 1, 2019
Study Registration Dates
First Submitted
May 22, 2014
First Submitted That Met QC Criteria
June 5, 2014
First Posted (Estimate)
June 9, 2014
Study Record Updates
Last Update Posted (Actual)
October 16, 2019
Last Update Submitted That Met QC Criteria
October 14, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UM-HUM00073474
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Ohio State UniversityCompletedSepsis, Severe Sepsis and Septic ShockUnited States
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRecruitingSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
Zagazig UniversityRecruitingSepsis-associated EncephalopathyEgypt
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital and other collaboratorsCompletedSepsis | Septic Shock | Severe Sepsis | Infection | Sepsis SyndromeUnited States
Clinical Trials on Additional physical therapy
-
Ohio State UniversityUniversity of Missouri-Columbia; University of Alabama at Birmingham; University... and other collaboratorsCompletedEffectiveness of Virtual Reality Gaming Therapy Versus CI Therapy for Upper Extremity RehabilitationStroke | HemiparesisUnited States
-
Hospices Civils de LyonRecruitingCovid19 | Respiratory Distress Syndrome | Ventilators, MechanicalFrance
-
Charles University, Czech RepublicCompleted
-
Universitaire Ziekenhuizen KU LeuvenKU Leuven; Research Foundation FlandersCompleted
-
UMC UtrechtDutch Pancreatic Cancer Group (DPCG)Enrolling by invitationRecurrent Pancreatic Ductal AdenocarcinomaNetherlands
-
Riphah International UniversityCompleted
-
Mayo ClinicDePuy OrthopaedicsCompleted
-
International Hellenic UniversityNot yet recruitingChronic Pain | Neuropathic Pain | Cognitive Therapy
-
Universidad de ZaragozaCompletedPlagiocephaly | Plagiocephaly, Nonsynostotic | Plagiocephaly, PositionalSpain